本文選題：和中止鼽方 + 穴位注射��； 參考：《西南醫(yī)科大學(xué)》2016年碩士論文

【摘要】：目的:探討和中止鼽方配合穴位注射治療肺脾氣虛型變應(yīng)性鼻炎(Allergic rhinitis,AR)的臨床療效,為和中止鼽方配合穴位注射療法在臨床應(yīng)用推廣提供支撐依據(jù)。方法:采用兩個中心(西南醫(yī)科大學(xué)附屬中醫(yī)醫(yī)院及重慶市墊江縣中醫(yī)院)隨機(jī)對照試驗方法,本研究所納入的患者均為2015年8月至2016年1月就診的AR患者,應(yīng)用口服和中止鼽方湯劑配合穴位注射的方法治療,并與應(yīng)用口服氯雷他定分散片配合布地奈德鼻用氣霧劑噴鼻相比較,依照納入與排除標(biāo)準(zhǔn),共收集了臨床確診的肺脾氣虛型AR52例有效病例,其中治療組26例,口服和中止鼽方湯劑,每次量200ml,每日1劑,連服7日,隔7日后再服7日,同時行雙側(cè)迎香穴穴位注射,每周1次,3周為一個療程;對照組26例采用口服氯雷他定分散片,每晚一片,連服14日,同時使用布地奈德鼻用氣霧劑噴鼻,早晚各一次,3周為一個療程。治療結(jié)束后門診隨訪4周。在患者治療前、治療結(jié)束后1周及治療結(jié)束后4周進(jìn)行視覺模擬評分量表(visual analogue scale,VAS)評分、鼻眼結(jié)膜相關(guān)生活質(zhì)量問卷調(diào)查量表(Rhinocoujunctivitis Quality of Life Questionaire)(中文版自測版本)評分以及鼻內(nèi)鏡檢查評分,通過比較評估臨床療效。結(jié)果:1、治療前兩組患者VAS、RQLQ積分比較無差異,P0.05;完成治療后1周,治療組患者VAS、RQLQ積分明顯低于對照組,P0.05;完成治療4周后,治療組患者VAS、RQLQ積分明顯低于對照組,P0.05。2、在治療前,兩組患者單項癥狀VAS評分及鼻部體征比較無明顯差異,P0.05;完成治療一周后,治療組患者在鼻塞、噴嚏和鼻部體征的比較中積分低于對照組,P0.05;在完成治療4周后,治療組患者鼻塞、鼻癢、噴嚏、流體等鼻部癥狀及鼻部體征均積分均明顯低于對照組,P0.05。3、治療組患者顯效12例(48.0%),有效12例(48.0%),無效1例(4.0%),總有效24例,總有效率為96.0%。對照組患者顯效8例(33.3%),有效7例(29.2%),無效9例(37.5%),總有效15例,總有效率為62.5%,P0.05。結(jié)論:和中止鼽方配合穴位注射治療可以提高肺脾氣虛型AR患者的臨床治療有效率,同時也可以有效改善AR患者的臨床癥狀,提升患者生活質(zhì)量。
[Abstract]:Objective: to investigate the clinical effect of Qiu prescription combined with acupoint injection in the treatment of allergic rhinitis ARA with asthenia of lung and spleen qi, and to provide the support basis for the clinical application and popularization of Qiu prescription and acupoint injection therapy. Methods: two centers (affiliated traditional Chinese Medicine Hospital of Southwest Medical University and Chongqing Dianjiang traditional Chinese Medicine Hospital) were used in the randomized controlled trial. The patients included in the study were AR patients from August 2015 to January 2016. Oral and stop Qiu decoction combined with acupoint injection were used, and compared with oral loratadine dispersible tablets combined with budesonide nasal aerosol spray, according to the inclusion and exclusion criteria, A total of effective cases of lung and spleen qi deficiency type AR52 were collected. In the treatment group, 26 cases were treated by oral administration and Xiaoqifang decoction at a dose of 200 ml, 1 dose per day for 7 days, and 7 days after taking, at the same time, the treatment group was given bilateral Yingxiang acupoint injection. 26 patients in the control group were treated with oral loratadine dispersible tablets once a night for 14 days, and budesonide nasal spray with aerosol in the morning and evening. The patients were followed up for 4 weeks after treatment. Visual analogue scale (VAS) was performed before treatment, 1 week after treatment and 4 weeks after treatment. The Rhinocoujunctivitis Quality of Life questionnaire scale (Rhinocoujunctivitis Quality of Life questionnaire) and the nasal Endoscopy scale (ESS) were used to evaluate the clinical efficacy. Results there was no significant difference in the RQLQ scores between the two groups before and after treatment (P0.05). The RQLQ scores of the patients in the treatment group were significantly lower than those in the control group (P0.05) one week after the completion of treatment. After 4 weeks of treatment, the RQLQ scores of the patients in the treatment group were significantly lower than those in the control group (P0.05.2), and before the treatment, the RQLQ scores of the patients in the treatment group were significantly lower than those in the control group (P < 0.05). There was no significant difference in single symptom VAS score and nasal signs between the two groups (P 0.05). After one week of treatment, the scores of nasal congestion, sneezing and nasal signs in the treatment group were lower than those in the control group (P 0.05); after 4 weeks of treatment, the nasal obstruction in the treatment group was lower than that in the control group. The scores of nasal symptoms, symptoms and signs of nasal itch, sneeze and fluid were significantly lower than those of control group (P 0.05.3). In the treatment group, 12 cases had remarkable effect (48.0%), 12 cases had effective measures (48.0%), 1 case had no effect (4.0%), 24 cases were effective, and the total effective rate was 96.0 鈩，

本文編號：1972674